Leveraging Homologous Recombination Deficiency for Sarcoma
Author Information
Author(s): Planas-Paz Lara, Pauli Chantal
Primary Institution: University Hospital Zurich
Hypothesis
We aimed to investigate predictive biomarkers of HRD in several independent sarcoma cohorts and evaluate the therapeutic potential of PARP inhibitors.
Conclusion
We provide a personalized oncological approach to potentially improve the treatment of sarcoma patients.
Supporting Evidence
- Homologous recombination deficiency (HRD) in tumors correlates with poor prognosis and metastases development.
- Distinct SARC-HRD transcriptional signatures predicted sensitivity to PARP inhibitors.
- Functional defects in HRR in sarcoma cells were associated with dependency towards PARP inhibitors.
Takeaway
This study looks at how some sarcomas can be treated better by understanding their genetic weaknesses, especially using special drugs that target DNA repair.
Methodology
We performed genomic and transcriptomic characterization of sarcoma using datasets from TCGA and TARGET, and evaluated PARP1/2 and WEE1 inhibition ex vivo in patient-derived sarcoma cell models.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website